帕利哌酮缓释片治疗急性精神分裂症疗效及安全性的对照分析

Comparative analysis of curative effect and safety by paliperidone extended-release tablets in the treatment of acute schizophrenia

目的探讨帕利哌酮缓释片在急性精神分裂症患者中的应用效果及其安全性。方法 68例急性精神分裂症患者,根据随机数字法分为对照组和治疗组,各34例。临床分别给予其利培酮和帕利哌酮缓释片治疗,观察对比两种不同治疗方法的应用效果。结果治疗后治疗组患者阳性与阴性症状量表(PANSS)评分为(56.2±5.1)分,治疗总有效率为94.1%,对照组患者PANSS评分为(72.3±8.5)分,治疗总有效率为82.4%,两组患者PANSS评分和治疗总有效率相比差异均有统计学意义(P<0.05)。治疗后,治疗组和对照组患者不良反应发生率比较差异无统计学意义(P>0.05)。结论急性精神分裂症采用帕利哌酮缓释片治疗,可有效缓解患者临床症状,降低其PANSS评分,且用药后患者不良反应发生率较低,治疗效果良好,具有临床推广价值。

Objective To investigate curative effect and safety by paliperidone extended-release tablets in the treatment of acute schizophrenia. Methods A total of 68 patients with acute schizophrenia were divided by random number table into control group and treatment group, with 34 cases in each group. They respectively received risperidone and paliperidone extended-release tablets for clinical treatment. Application effects of the two treatment ways were observed and compared. Results The treatment group had positive and negative syndrome scale （PANSS） score as （56.2 ± 5.1） points and total effective rate as 94.1% after treatment. Those in the control group were respectively （72.3± 8.5） points and 82.4%. There were statistically significant differences of PANSS score and total effective rate between the two groups （P〈0.05）. After treatment, the difference of incidence of adverse reactions had no statistical significance between the two groups （P〉0.05）. Conclusion Implement of paliperidone extended-release tablets in the treatment of acute schizophrenia can effectively relieve clinical symptoms and reduce PANSS score and incidence of adverse reactions in patients, along with excellent curative effect. This method contains value for clinical promotion.